Related Experiment Video
Updated: Jun 6, 2026

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues
Published on: June 16, 2018
PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis
Raúl Catena1, Diego Luis-Ravelo, Iker Antón
1Novel Therapeutics Targets, Division of Oncology, Center for Applied Biomedical Research (CIMA), University of Navarra, Pamplona, Spain.
Abstract:
Bone microenvironment and cell-cell interactions are crucial for the initiation and development of metastasis. By means of a pharmacologic approach, using the multitargeted tyrosine kinase inhibitor sunitinib, we tested the relevance of the platelet-derived growth factor receptor (PDGFR) axis in the bone marrow (BM) stromal compartment for the initiation and development of lung cancer metastasis to bone. PDGFRβ was found to be the main tyrosine kinase target of sunitinib expressed in BM stromal ST-2 and MC3T3-E1 preosteoblastic cells. In contrast, no expression of sunitinib-targeted receptors was found in A549M1 and low levels in H460M5 lung cancer metastatic cells. Incubation of ST-2 and human BM endothelial cells with sunitinib led to potent cell growth inhibition and induction of apoptosis in a dose-dependent manner. Similarly, sunitinib induced a robust proapoptotic effect in vivo on BM stromal PDGFRβ(+) cells and produced extensive disruption of tissue architecture and vessel leakage in the BM cavity. Pretreatment of ST-2 cells with sunitinib also hindered heterotypic adhesion to lung cancer cell lines. These effects were correlated with changes in cell-cell and cell-matrix molecules in both stromal and tumor cells. Pretreatment of mice with sunitinib before intracardiac inoculation of A549M1 or H460M5 cells caused marked inhibition of tumor cells homing to bone, whereas no effect was found when tumor cells were pretreated before inoculation. Treatment with sunitinib dramatically increased overall survival and prevented tumor colonization but not bone lesions, whereas combination with zoledronic acid resulted in marked reduction of osteolytic lesions and osseous tumor burden. Thus, disruption of the PDGFR axis in the BM stroma alters heterotypic tumor-stromal and tumor-matrix interactions, thereby preventing efficient engagement required for bone homing and osseous colonization. These results support the notion that concomitant targeting of the tumor and stromal compartment is a more effective approach for blocking bone metastasis.
Insights
Sunitinib targets platelet-derived growth factor receptor beta (PDGFRβ) in bone marrow stroma, inhibiting lung cancer metastasis to bone by disrupting tumor-stromal interactions. Combination therapy with zoledronic acid further reduces bone lesions.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Bone metastasis initiation and development depend on the bone microenvironment and cell-cell interactions.
- The platelet-derived growth factor receptor (PDGFR) axis in bone marrow stroma plays a role in lung cancer metastasis to bone.
Purpose of the Study:
- To investigate the relevance of the PDGFR axis in the bone marrow stromal compartment for lung cancer metastasis to bone using the tyrosine kinase inhibitor sunitinib.
- To evaluate the efficacy of sunitinib in preventing bone metastasis and improving survival.
Main Methods:
- Pharmacologic approach using sunitinib, a multitargeted tyrosine kinase inhibitor.
- In vitro studies on bone marrow stromal cells (ST-2, MC3T3-E1) and human bone marrow endothelial cells.
- In vivo studies using a mouse model of lung cancer bone metastasis.
Main Results:
- Sunitinib primarily targets PDGFRβ in bone marrow stromal cells, inhibiting their growth and inducing apoptosis.
- Sunitinib disrupted tissue architecture and vessel leakage in the bone marrow and hindered heterotypic adhesion between stromal and lung cancer cells.
- Pretreatment of mice with sunitinib inhibited tumor cell homing to bone and increased overall survival, while combination with zoledronic acid reduced osteolytic lesions.
Conclusions:
- Disruption of the PDGFR axis in bone marrow stroma by sunitinib prevents lung cancer cell homing and colonization in bone.
- Targeting both tumor and stromal compartments concurrently is a more effective strategy for blocking bone metastasis.
